Eli Lilly’s $2.75B AI deal with Insilico Medicine targets age-related diseases. How AI is transforming longevity drug discovery and what it means for patients.
Eli Lilly’s $2.75 Billion AI Bet on Anti-Aging Drugs Signals a Major Shift in Pharmaceutical Priorities
by | Jun 12, 2026 | Uncategorized | 0 comments
Recent Comments